Method for Identifying and Screening Dendritic Killer Cells
A method for identifying and screening dendritic killer cells (DKC) is disclosed in the present invention, and the method is to identify a plurality of cell surface markers selected from a group consisting of HLA-G − , CD14 − , CD3 - , CD19 − , CD56 dim and HLA-DR + . The method for screening DKC from human peripheral blood mononuclear cells (PBMC) comprises the following steps. A first cell population with regular cell size is provided and a second cell population is then sorted out from the first cell population by screening the phenotype of CD14 and HLA-G therein. A third cell group is further sorted out from the second cell population by screening the phenotype of CD19 and CD3 therein. Finally, DKC will be identified out of the third cell population by screening the phenotype of CD56 and HLA-DR.
1 . A method for identifying dendritic killer cell (DKC) involving identifying a plurality of cell surface markers selected from a group consisting of natural killer cell surface markers, dendritic cell surface markers and HLA-G − .
2 . The method according to claim 1 , wherein the natural killer cell surface markers comprise CD56 + .
3 . The method according to claim 2 , wherein CD56 + is CD56 dim .
4 . The method according to claim 1 , wherein the dendritic cell surface markers comprise HLA-DR + .
5 . The method according to claim 1 , wherein the group further consists of a lack of expression of a mononuclear cell surface marker, a B cell surface marker and a T cell surface marker.
6 . The method according to claim 5 , wherein the lack of expression of the mononuclear cell surface marker, the B cell surface marker and the T cell surface marker are CD14 − , CD19 − and CD3 − .
7 . The method according to claim 1 , the method can identify the dendritic killer cell from a human peripheral blood sample.
8 . The method according to claim 7 , wherein the human peripheral blood is obtained from a cancer patient.
9 . A method for screening dendritic killer cell, comprising at least following steps:
providing a first cell population;
sorting out a second cell population from the first cell population by screening the phenotype of CD14 and HLA-G therein;
sorting out a third cell population from the second cell population by screening the phenotype of CD19 and CD3 therein; and
sorting out a dendritic killer cell population from the third cell population by screening the phenotype of HLA-DR and CD56 therein.
10 . The method according to claim 9 , wherein the second cell population comprises the cells with the surface markers of CD 14 − and HLA-G.
11 . The method according to claim 9 , wherein the third cell population comprises the cells with the surface markers of CD14 − , CD3 − and CD19 − .
12 . The method according to claim 9 , wherein the surface marker of the dendritic killer cell population is CD14 − HLA-G − CD3 − CD19 − HLA-DR + CD56 dim .
13 . The method according to claim 9 , further comprising following steps:
collecting human peripheral blood; and
sorting out a first cell population by the size and the granularity of the cells.
14 . The method according to claim 13 , wherein the human peripheral blood is collected from a cancer patient.
15 . The method according to claim 9 , wherein the first cell population comprises Lymphoid cells and Monocytic cells.
16 . The method according to claim 9 , wherein the sorting steps are performed by using a flow cytometer.
17 . An isolated human dendritic killer cell, wherein the DKC is HLA-G − CD14 − CD19 − CD3 − CD56 + HLA-DR + .